A key focus of Mayne Pharma is to develop therapies and solutions that measurably improve individual’s lives. Mayne Pharma is focused on the following therapeutic areas to bring innovative products to clinicians, pharmacists and patients.
Mayne Pharma has an extensive women's health portfolio focused on contraceptives. Its pipeline includes a novel oral contraceptive E4/DRSP and a number of branded generic contraceptives.
Mayne Pharma is committed to making a difference in dermatology and is dedicated to marketing high quality and effective drugs. Mayne Pharma also continues to invest in R&D to bring new therapies to market that help patients achieve their goals of healthy skin.
Mayne Pharma’s patented technology significantly increases the absorption of existing antifungal compounds allowing for equivalent treatment outcomes from reduced dose administration.
Mayne Pharma has developed and markets a range of analgesic products, including immediate and extended-release as well as single and combination products.